logowsbdaily | Mon, 27 Jun 2022 02:58:49 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

GBS Inc.
(GBS)

GBS Inc.
420 Lexington Avenue
Suite 300
New York, NY 10170
United States
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the... Read More

Summary & Charts

Price$ 0.74-0.05 (-6.33%)
Day's Range$ 0.74 - 0.82 
Previous Close$ 0.79
Market Cap$ 11.01M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqCM
IndustryMedical Devices
SectorHealthcare
Volume83.28K
Avg. Volume (20 day)93.66K
Rel. Volume (20 day)0.89
Rel. Volume (3 month)0.13
RatingA-Buy
DCFN/AStrong Buy
Debt/Equity64.47 %Buy
ROE-30.56 %Sell
ROA-25.24 %Neutral
P/E-3.04 %Sell
P/B1.25 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Jun 24, 2022$ 0.81$ 0.82$ 0.74$ 0.74-0.0583,2760.890.131
Jun 23, 2022$ 0.77$ 0.80$ 0.72$ 0.79+0.0495,6341.050.15
Jun 22, 2022$ 0.66$ 0.75$ 0.66$ 0.75+0.09249,9572.890.312
Jun 21, 2022$ 0.64$ 0.67$ 0.60$ 0.67+0.01103,0211.320.132
Jun 17, 2022$ 0.62$ 0.66$ 0.56$ 0.66+0.0694,1211.260.12
Jun 16, 2022$ 0.56$ 0.60$ 0.53$ 0.59+0.01189,0352.660.243
Jun 15, 2022$ 0.57$ 0.59$ 0.56$ 0.58-0.0076,9171.150.09
Jun 14, 2022$ 0.57$ 0.62$ 0.57$ 0.58+0.0129,1180.390.03
Jun 13, 2022$ 0.58$ 0.60$ 0.57$ 0.57-0.01122,7031.010.10
Jun 10, 2022$ 0.65$ 0.65$ 0.57$ 0.58-0.0390,2520.760.04
Jun 09, 2022$ 0.64$ 0.64$ 0.60$ 0.62+0.0239,1380.330.02
Jun 08, 2022$ 0.60$ 0.63$ 0.57$ 0.60+0.03139,8541.170.06
Jun 07, 2022$ 0.57$ 0.58$ 0.57$ 0.57-0.00138,7641.200.06
Jun 06, 2022$ 0.57$ 0.61$ 0.57$ 0.57+0.0044,7150.380.02
Jun 03, 2022$ 0.59$ 0.60$ 0.57$ 0.57+0.0058,9240.470.02
Jun 02, 2022$ 0.60$ 0.60$ 0.57$ 0.57-0.0223,2010.180.011
Jun 01, 2022$ 0.59$ 0.60$ 0.58$ 0.59+0.0153,3230.410.02
May 31, 2022$ 0.58$ 0.60$ 0.56$ 0.58-0.0176,1320.590.03
May 27, 2022$ 0.59$ 0.62$ 0.56$ 0.59+0.0197,0070.760.04
May 26, 2022$ 0.62$ 0.62$ 0.58$ 0.58-0.0168,1610.540.03

News

The latest news about GBS Inc. (GBS).

GlobeNewsWire | 2022-05-16 16:05:00
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. Please see additional details below:
Seeking Alpha | 2022-05-14 23:28:18
GBS Inc. (NASDAQ:GBS ) Q3 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dr. Steven Boyages - Chairman and Interim CEO Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the GBS Inc. Third Quarter 2022 Earnings Conference Call.
GlobeNewsWire | 2022-05-03 09:05:00
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-05-10AMC-0.16-0.0943.76%------
2022-02-10AMC-0.16-0.2343.75%1651777.27%
2021-11-11AMC------------
2021-08-11AMC------------

Due Diligences

These posts should include more in-depth research by the poster about the specific company, sector or trade idea. Including any sources and citations.

$GBS $0.60 NASDAQ stock should easily double based on todays news they are acquiring a fingerprint sweat-based drug screening company

GBS is already in the process of disrupting the diabetes market with their saliva glucose testing vs having to prick yourself and draw blood to test in a glucose meter. Their saliva testing costs a fraction of a penny each test vs up to a $1+ per test strip for using blood and it is pain free. Now... Read More

4 comments | 5 votes

Top Discussions

These are the top discussions over the last 24-hours that mention the GBS stock ticker symbol.

Daily Plays June 24, 2022

Talk about your plays today or things you are on the lookout for. This is where you belong if your comment includes a $Ticker in that format. ​ *keep it civil please*...


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Mon, 13 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.